<DOC>
<DOCNO>EP-0646132</DOCNO> 
<TEXT>
<INVENTION-TITLE>
AMINO SUGARS, GLYCOPROTEINS, METHOD OF PREPARING THEM, MEDICINES CONTAINING THEM AND THEIR USE
</INVENTION-TITLE>
<CLASSIFICATIONS>C12P2100	A61P3500	A61K3800	A61P3302	A61P3500	C07K200	A61P908	A61K3800	C07K200	A61P3300	A61P900	A61P900	C07K1400	C07K1400	A61P3100	A61P3104	A61P3704	C12R191	A61P3112	C12P2100	A61P3700	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C12P	A61P	A61K	A61P	A61P	C07K	A61P	A61K	C07K	A61P	A61P	A61P	C07K	C07K	A61P	A61P	A61P	C12R	A61P	C12P	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C12P21	A61P35	A61K38	A61P33	A61P35	C07K2	A61P9	A61K38	C07K2	A61P33	A61P9	A61P9	C07K14	C07K14	A61P31	A61P31	A61P37	C12R1	A61P31	C12P21	A61P37	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The invention pertains to new amino sugars (neuraminic acid precursor analogues) and new glycoproteins, methods of preparing them, pharmaceutical agents containing them and their use in stimulating growth and differentiation of human and animal cells of the immune system and in preventing the adhesion of leucocytes, thrombocytes and tumor cells to vascular endothelium cells, also in stimulating the immune system, especially T-lymphocytes, warding off infections and treating weaknesses in the immune system, tumorous illnesses including metastatic processes, infectious diseases (viruses, bacteria, parasites, protozoa) and circulatory failures, especially vascular occlusions and septicemia, in humans and animals.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
REUTTER WERNER
</APPLICANT-NAME>
<APPLICANT-NAME>
REUTTER, WERNER
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
KAYSER HOLGER
</INVENTOR-NAME>
<INVENTOR-NAME>
KEPPLER OLIVER
</INVENTOR-NAME>
<INVENTOR-NAME>
PAWLIKA MICHAEL
</INVENTOR-NAME>
<INVENTOR-NAME>
REUTTER WERNER
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHUELER CORA
</INVENTOR-NAME>
<INVENTOR-NAME>
KAYSER, HOLGER
</INVENTOR-NAME>
<INVENTOR-NAME>
KEPPLER, OLIVER
</INVENTOR-NAME>
<INVENTOR-NAME>
PAWLIKA, MICHAEL
</INVENTOR-NAME>
<INVENTOR-NAME>
REUTTER, WERNER
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHUELER, CORA
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Glycoproteins having the general formula (I)


wherein

Z represents -NHR wherein R is a pentanoyl, hexanoyl, heptanoyl or crotonoyl
residue or a mono- or multi-hydroxylated analogue of one of these residues,
R
1
, R
1'
, R
1"
, R
2
, R
3
, R
4
 and R
5
 which can be the same or different each represent
a hydrogen atom; a linear or branched alkyl residue containing 1 to 20

carbon atoms (C
n
H
2n+2
, n = 1 to 20), preferably 1 to 7 carbon atoms; a linear
or branched alkenyl residue containing 3 to 20 carbon atoms (C
n
H
2n
, n = 3 to 
20; double bond in C
n
 at C2 to C19 position), preferably 3 to 10 carbon atoms;
a linear or branched alkynyl residue containing 3 to 20 carbon atoms

(C
n
H
2n-2
, n = 3 to 20; triple bond in C
n
 at C2 to C19 position), preferable 3 to
10 carbon atoms; an alkenyl or alkynyl residue having 2 or more double and

triple bonds respectively, and containing 4 to 20, preferably 7 to 12 carbon
atoms; an aryl residue containing 6 to 20 carbon atoms, preferably a phenyl

residue; a linear or branched, saturated or mono- or multi-unsaturated acyl
residue (-CO-R
1
), containing a total of 1 to 20, preferably 1 to 7 carbon atoms,
including its mono- or multi-hydroxylated analogues; an aroyl residue containing

6 to 20, preferably 6 to 10 carbon atoms; a carbonylamide residue of the

formula -CONH
2
, -CONHR
1
, -CONR
1
R
1'
 or -CONR
1
R
1'
R
1"
 ; a linear or branched,
saturated or mono- or multi-unsaturated thioacyl residue (-CS-R
1
), containing
a total of 1 to 20, preferably 1 to 7 carbon atoms; or a thiocarbamide

residue of the formula -CS-NH
2
, -CS-NHR
1
, -CS-NR
1
 R
1'
 or -CS-NR
1
R
1'
R
1"
;

wherein each of the aforementioned residues, with the exception of H, optionally
can be singly or multiply substituted by halogen, preferably fluorine,

chlorine, bromine or iodine, hydroxy, epoxy, amino, mercaptane, phenyl, phenol
or benzyl groups; and
T represents a mono-, di- or oligosaccharide residue with up to 40 glycosidically
linked, optionally or branched sugar residues representing furanose and/or

pyranose rings, linked N- or O-glycosidically to the polypeptide and containing
5 to 230 carbon atoms; and

glycoproteins having the general formula (I'), which serve as a glycosylphosphatidylinositol(GPI)
anchor: 



where

Gal =
galactose,
Man =
mannose,
Asp =
asparagine,
GlcN =
glucosamine,

and in which GlcN can be replaced by an analogue of a neuraminic acid
precursor having the formula (II)



wherein R
1
, R
2
 and R
3
 have the same meaning as above and Z' is the same
as Z and can occupy an equatorial position as well as an axial position and

wherein furthermore, if Z' occupies the equatorial position, the axial position
can be occupied by -OR
2
.
The compounds according to claim 1, characterized in that T in general
formula (I) represents either 

a saccharide residue having an N-glycan structure having the formula (la)


where

Gal =
galactose,
GN =
N-acetyl-D-glucosamine,
M =
D-mannose,
Fuc =
fucose,
Asn =
asparagine,
X =
any amino acid except proline,
Thr =
threonine,
Ser =
serine,
* =
attachment site of T (1 to 6 molecular residues),

in which both peripheral M residues can be substituted by 1 to 3 trisaccharides;
or

a saccharide residue having an 0-glycan structure having the general formula
(Ib):


 
where


Gal =
galactose
Thr =
threonine
Ser =
serine
Xyl =
xylose
NAcGal =
N-acetylgalactosamine
* =
attachment site of T,

and wherein in the above formulae (la) and (Ib), galactose (Gal) can be replaced
by 2-deoxy-galactose or 2-deoxy-2-halide(F, Cl, Br, I)-galactose.
The compounds according to claim 1 and/or 2, characterized in that when
T is a saccharide residue having an N-glycan or an O-glycan structure, GN is a

residue of the general formula (II):


wherein R
1
, R
2
 and R
3
 have the meaning as defined in claim 1; and Z' is the
same as Z and can occupy an equatorial position as well as an axial position;

and wherein furthermore, if Z' occupies the equatorial position, the axial position
can be accupied by -OR
2
.
The compounds according to at least one of claims 1 to 3, characterized in
that R
2
 to R
5
 represent H or CH
3
.
Aminosugars (analogues of neuraminic acid precursors) having the general
formula (II): 



wherein Z' and R
1
, R
2
 and R
3
 have the same meaning as defined in claims 1
to 4.
A method for the in vivo-preparation of the compounds according to claims
1 to 5 by parenteral or enteral administration to humans or animals of a 2-deoxy-2-amino-mannose,

-glucose or -galactose, wherein the amino group is
substituted by R
1
 ; preferably of N-pentanoyl-, N-hexanoyl-, N-heptanoyl- or N-crotonoyl-D-mannosamine.
The method according to claim 6, characterized in that the in vivo-synthesized
glycoproteins of claims 1 to 4 are obtained(separated) in a manner

known per se and are used therapeutically.
A pharmaceutical preparation characterized in that it contains as an active
constituent, optionally in combination with other active constituents, usual

pharmaceutical vehicles and/or auxiliary substances, at least one glycoprotein
having the formula (I)



wherein 

Z represents -NHR wherein R is a pentanoyl, hexanoyl, heptanoyl or crotonoyl
residue or a mono- or multi-hydroxylated analogue of one of these residues,
R
1
, R
1'
, R
1"
, R
2
, R
3
, R
4
 and R
5
 which can be the same or different each represent
a hydrogen atom; a linear or branched alkyl residue containing 1 to 20

carbon atoms (C
n
H
2n+2
, n = 1 to 20), preferably 1 to 7 carbon atoms; a linear
or branched alkenyl residue containing 3 to 20 carbon atoms (C
n
H
2n
, n = 3 to
20; double bond in C
n
 at C2 to C19 position), preferably 3 to 10 carbon atoms;
a linear or branched alkynyl residue containing 3 to 20 carbon atoms (C
n
H
2n-2
,
n = 3 to 20; triple bond in C
n
 at C2 to C19 position), preferable 3 to 10 carbon
atoms; an alkenyl or alkynyl residue having 2 or more double and triple

bonds respectively, and containing 4 to 20, preferably 7 to 12 carbon atoms;
an aryl residue containing 6 to 20 carbon atoms, preferably a phenyl residue; a

linear or branched, saturated or mono- or multi-unsaturated acyl residue (-CO-R
1
),
containing a total of 1 to 20, preferably 1 to 7 carbon atoms, including its

mono- or multi-hydroxylated analogues; an aroyl residue containing 6 to 20,
preferably 6 to 10 carbon atoms; a carbonylamide residue of the formula

-CONH
2
, -CONHR
1
, -CONR
1
R
1'
 or -CONR
1
R
1'
R
1"
; a linear or branched,
saturated or mono- or multi-unsaturated thioacyl residue (-CS-R
1
), containing
a total of 1 to 20, preferably 1 to 7 carbon atoms; or a thiocarbamide residue of

the formula -CS-NH
2
, -CS-NHR
1
, -CS-NR
1
R
1'
 or -CS-NR
1
R
1'
R
1"
; wherein
each of the aforementioned residues, with the exception of H, optionally can

be singly or multiply substituted by halogen, preferably fluorine, chlorine, bromine
or iodine, hydroxy, epoxy, amino, mercaptane, phenyl, phenol or benzyl

groups; and
T represents a mono-, di- or oligosaccharide residue with up to 40 glycosidically
linked, optionally branched sugar residues representing furanose and/or

pyranose rings, linked N- or O-glycosidically to the polypeptide and containing

5 to 230 carbon atoms; and/or
 
at least one glycoprotein having the general formula (I'), which serve as a glycosylphosphatidylinositol(GPI)

anchor:


where

Gal =
galactose,
Man =
mannose,
Asp =
asparagine,
GlcN =
glucosamine,

and in which GlcN can be replaced by an analogue of a neuraminic acid
precursor having the formula (II)



wherein R
1
, R
2
 and R
3
 have the same meaning as above and Z' is the same
as Z and can occupy an equatorial position as well as an axial position and 

wherein furthermore, if Z' occupies the equatorial position, the axial position
can be occupied by -OR
2
.
The pharmaceutical preparation according to claim 8, characterized in that
it contains the active constituent in an amount of 0.1 to 50% by weight, preferably

0.1 to 20 % by weight, especially 2 to 10% by weight.
The pharmaceutical preparation according to claim 8 or 9 for stimulation
of the immune system, in particular of the T-lymphocytes, for the protection

against infection, for the treatment of a weak immune response, of tumor diseases
including processes of metastasis, of infectious diseases (caused by

viruses, bacteria, parasites, protozoa) and of circulatory collapse, in particular
vascular obliterations and septicaemia, in humans and animals.
The pharmaceutical preparation according to claim 8 or 9 for increasing
the cytotoxic activity of natural killer cells (NK cells) for inducing an antitumor

immune-reaction in humans and animals.
The pharmaceutical preparation according to claim 8 or 9 for increasing
the phagocytic activity of granulocytes and monocytes for the induction of an

anti-tumor immune-reaction in humans and animals
The pharmaceutical preparation according to claim 8 or 9 for the in vivo-modulation
of neuraminic acid-dependent processes.
The pharmaceutical preparation according to claim 8 or 9 for the inhibition
of the ligand binding to sialylated cell surface receptors (endothelial cells,

thrombocytes, leucozytes).
The pharmaceutical preparation according to claim 8 or 9 for the inhibition
of the binding of a pathogenic microorganism (virus, bacterium, parasite, protozoan) 

or of a toxin to a host cell via a sialylated receptor by in vivo-modulation
of neuraminic acids.
The pharmaceutical preparation according to claim 8 or 9 for stimulation
of the growth and differentiation of human and animal cells of the immune system,

and for preventing adhesion of leucozytes, thrombocytes and tumor cells
to vascular endothel cells.
The pharmaceutical preparation according to claim 8 or 9 for the biosynthetic
preparation of ligands or receptors with modified neuraminic acid, and its

use as physiological or pathological competitors of ligand-receptor interactions.
The pharmaceutical preparation according to claim 8 or 9 for the in vitro-modulation
of the course of infection by human immune deficiency viruses e.g.

HIV-1 and HIV-2 as well as for the in vivo prevention of infection by human
immune deficiency viruses e.g. HIV-1 and HIV-2.
The pharmaceutical preparation according to claim 8 or 9 for the treatment
of parasitic diseases, in particular trypanosomiasis, leishmaniasis,

trichomoniasis, giardiasis, amoebiasis, malaria, pneumocystosis, schistosomiasis
(Bilharzia) and echinococcosis.
</CLAIMS>
</TEXT>
</DOC>
